Particle News: Latest Sarepta Therapeutics news

FDA Investigates Fatal Liver Failures Linked to Sarepta’s Elevidys Therapy

Two teenage deaths within 90 days of infusion prompted Sarepta to suspend shipments to non-ambulatory patients.

Sarepta Shares Plummet on FDA Review of Elevidys Following Third Patient Death

FDA Reinstates Biologics Director Vinay Prasad Less Than Two Weeks After Resignation

Sarepta Defies FDA, Keeps Duchenne Gene Therapy on the Market

FDA Lifts Hold on Elevidys Shipments to Ambulatory Duchenne Patients

FDA Flags Possible License Revocation for Sarepta’s Elevidys

First Death Reported from Sarepta's Duchenne Gene Therapy Raises Safety Concerns

Vinay Prasad Resigns as FDA Biologics Director After Politicized Tenure

FDA Brings Back Vinay Prasad to Lead Biologics Unit After Brief Exit

Sarepta Temporarily Halts Elevidys Shipments Under FDA Request

White House Aides Push Back as Laura Loomer’s Outsider Influence Drives Firings and Visa Pause

Regulators Halt Elevidys Gene Therapy Worldwide After Safety Failures